Minapharm Pharmaceuticals
EEGX:MIPH742.36
EGP
-5.74
(-0.77%)
ISIN
EGS380G1C011
Return %
Stock
S&P 500
1Y
127.79
14.20
3Y
264.80
81.12
5Y
612.85
68.34
Capital Structure
EGP
•
in mil. unless spec.Working Capital
EGP
•
in mil. unless spec.Growth Rates
EGP
•
in mil. unless spec.Quarterly Revenue
EGP
•
in mil. unless spec.Quarterly Earnings Per Share
EGP
•
in mil. unless spec.Quarterly Dividends Per Share
EGP
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Cairo Egypt
- IPO Date
- Jan 11, 2004
- Website
- minapharm.com
- Similar Companies
- Business
- Minapharm Pharmaceuticals S.A.E. is an Egypt-based biopharmaceutical company engaged in the research, development, manufacture, licensing, and commercialization of synthetic pharmaceuticals, complex bioengineered proteins, and biological therapeutics. Founded in 1958 and headquartered in Cairo, Egypt, the company operates an integrated gene-to-market business model serving domestic, regional Middle East and North Africa (MENA), and international markets across more than 30 export destinations. Minapharm conducts primary production, formulation, and packaging operations at its manufacturing complex in the 10th of Ramadan City, while executing global cell line engineering and bioprocess contract development through its wholly owned Berlin-based subsidiary, ProBioGen AG, alongside biosimilar commercialization through MiGenTra GmbH and specialized therapeutics via Rhein-Minapharm-Biogenetics. The company's comprehensive product and service portfolio comprises prescription pharmaceuticals and specialty medicines across therapeutic categories including cardiology, gastroenterology, neurology, nephrology, endocrinology, hematology, and women's health; recombinant proteins and therapeutic biologics, including interferons, anti-infectives, hematological agents, and antithrombotic therapies; sterile formulations, consisting of liquid injectables, lyophilized vials, ampoules, and ophthalmic drops; topical medications, dermatological preparations, and medicated dressings such as sterile tulle; and specialized contract development and manufacturing organization (CDMO) services, encompassing cell line development, proprietary expression platforms, viral vector manufacturing, bioprocess development, and analytical testing services for global pharmaceutical and biotechnology clients. In recent strategic developments, Minapharm has expanded its regional manufacturing footprint and vaccine development capabilities, entering into a multilateral partnership with the International AIDS Vaccine Initiative (IAVI) and ProBioGen to establish African manufacturing capacity for monoclonal antibodies and develop a Modified Vaccinia Ankara (MVA)-based Mpox vaccine. The company also secured partnership support from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its Bundibugyo ebolavirus vaccine candidate into clinical evaluation with technology transfer for drug substance production to its Cairo facility. Furthermore, through ProBioGen, the organization introduced the proprietary AGE1.CR.ReX designer cell line platform for high-titer poxvirus production, executed commercial CDMO agreements with international biopharma entities including VarmX and Polpharma Biologics, and implemented strategic executive leadership appointments to oversee expanded operations across its European subsidiaries and regional pipeline programs.